RxDoctor Payments Data

Rajeshwar Parmar, MD

Internal Medicine · Tucson, AZNPI 1417484882

Payments from drug & device makers

$1,843in general payments, 2019–2025

Across 40 payments — averaging $46.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$651
  • GSK$339
  • Novo Nordisk$227
  • Amgen$125
  • Silk Road Medical, Inc.$124
  • Abbott$76
  • plus $301 from 10 others

What the payments were for

  • Food & beverage$1,843100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,843 in reported general payments places this provider in the 80th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$59,195
Medicare patients
248
Services billed
524

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol34$35,172
OzempicSemaglutide14$16,919
TrulicityDulaglutide12$16,145
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$12,673
Lantus SolostarInsulin Glargine,hum.Rec.Anlog18$1,527
Albuterol Sulfate HfaAlbuterol Sulfate72$1,315
Atorvastatin Calcium104$930
Ultra-Fine Mini Pen NeedlePen Needle, Diabetic13$865
Gabapentin38$859
Metformin Hcl97$802
Levothyroxine Sodium67$595
Lisinopril81$568
Metoprolol Succinate33$440
Omeprazole23$426
Amlodipine Besylate55$374

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$651$35,17234 claims
Novo NordiskOzempic$227$16,91914 claims
Lilly USA, LLCTrulicity$75$16,14512 claims
GSKTrelegy Ellipta$339$12,67317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →